Pure Autonomic Failure
Pure autonomic failure (PAF), formerly known as Bradbury-Eggleston syndrome, is a rare neurodegenerative disorder characterized by progressive failure of the peripheral autonomic nervous system in the absence of motor, cerebellar, or significant cognitive involvement. PAF is an alpha-synucleinopathy with Lewy body deposition confined to peripheral autonomic ganglia and nerves, distinguishing it from other synucleinopathies such as Parkinson disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB) where central nervous system structures are prominently involved. The most critical clinical concern in PAF is the risk of phenoconversion — the evolution of isolated autonomic failure into a more widespread neurodegenerative disease — which fundamentally influences prognosis, counseling, and longitudinal monitoring.
Bottom Line
- Definition: Progressive autonomic failure without motor, cerebellar, or cognitive deficits — pure peripheral autonomic neurodegeneration
- Pathology: Alpha-synuclein (Lewy body) deposition confined to peripheral autonomic ganglia and nerves
- Epidemiology: Rare; onset in middle to late adulthood (50s–60s); slight male predominance
- Cardinal features: Severe neurogenic orthostatic hypotension, supine hypertension, urogenital dysfunction, constipation, sudomotor failure, fixed heart rate
- Phenoconversion risk: 14–34% convert to MSA, PD, or DLB over 5–10 years; REM sleep behavior disorder predicts PD/DLB conversion
- Key biomarker: Low supine plasma norepinephrine (<100 pg/mL) with failure to rise on standing — distinguishes peripheral (PAF) from central (MSA) autonomic failure
- Treatment: Directed at orthostatic hypotension (midodrine, droxidopa, fludrocortisone, non-pharmacologic measures); no disease-modifying therapy available
Pathophysiology
PAF is fundamentally a disorder of peripheral postganglionic sympathetic neurons, with alpha-synuclein aggregates (Lewy bodies and Lewy neurites) deposited in sympathetic ganglia, sympathetic nerve terminals innervating blood vessels and the heart, parasympathetic ganglia, and enteric neurons. This selective peripheral neurodegeneration accounts for the pattern of pan-autonomic failure without somatic motor or central nervous system dysfunction.
Key Pathophysiologic Features
- Postganglionic sympathetic denervation: Loss of norepinephrine-releasing nerve terminals in blood vessels → inability to vasoconstrict on standing → severe orthostatic hypotension
- Cardiac sympathetic denervation: Loss of sympathetic innervation to the heart → fixed heart rate, inability to increase HR in response to standing or exercise; demonstrated by reduced cardiac MIBG uptake
- Parasympathetic failure: Involvement of vagal and sacral parasympathetic neurons → impaired heart rate variability, bladder dysfunction, erectile dysfunction
- Enteric nervous system: Alpha-synuclein in enteric neurons → constipation, GI dysmotility
- Sudomotor denervation: Loss of postganglionic cholinergic sudomotor neurons → anhidrosis, heat intolerance
PAF as a Restricted Synucleinopathy
- Alpha-synuclein pathology is the same as in PD, DLB, and MSA, but is confined to the peripheral nervous system in PAF
- Skin biopsy studies have demonstrated alpha-synuclein deposits in dermal autonomic nerve fibers of PAF patients
- CSF alpha-synuclein levels may be reduced, similar to other synucleinopathies
- The "peripheral-first" hypothesis posits that synuclein pathology may begin in the periphery (gut, autonomic nerves) and spread centrally — PAF may represent an early stage where peripheral pathology has not yet propagated
- Alpha-synuclein seed amplification assays (SAA) can detect misfolded synuclein in CSF and may predict phenoconversion risk
Epidemiology
- Prevalence: Rare; estimated at 3–10 per 100,000 (likely underdiagnosed and misclassified)
- Age of onset: Typically 5th–7th decade (50s–60s)
- Sex distribution: Slight male predominance (M:F approximately 1.5–2:1)
- Progression: Insidious onset with gradual worsening of autonomic symptoms over years
- Survival: Generally favorable compared to MSA; most patients live for decades after diagnosis unless phenoconversion occurs
Clinical Features
The clinical presentation of PAF is dominated by pan-autonomic failure affecting cardiovascular, urogenital, gastrointestinal, and sudomotor domains. By definition, patients do not have significant motor, cerebellar, or cognitive deficits. The hallmark is severe neurogenic orthostatic hypotension.
Cardiovascular Autonomic Failure
- Severe orthostatic hypotension: Often the most prominent and disabling feature; SBP drops of 40–80 mmHg are common; worsened by meals, heat, exercise
- Supine hypertension: Present in the majority of PAF patients; SBP ≥160–180 mmHg when lying down; nocturnal supine HTN causes pressure natriuresis, worsening morning OH
- Fixed heart rate: Loss of both sympathetic and parasympathetic cardiac innervation; HR typically 60–80 bpm and unresponsive to postural change, Valsalva, or exercise
- Post-prandial hypotension: Exacerbated by meals due to splanchnic blood pooling without compensatory vasoconstriction
Urogenital Dysfunction
- Urinary retention: Incomplete bladder emptying due to detrusor underactivity (parasympathetic failure); may require intermittent catheterization
- Erectile dysfunction: Often an early symptom in men; may precede orthostatic symptoms by years
- Nocturia: Supine hypertension at night promotes renal sodium and water excretion (pressure natriuresis), contributing to nocturia and nocturnal polyuria
Gastrointestinal Dysfunction
- Constipation: Very common; slow colonic transit from enteric and autonomic nerve involvement
- Gastroparesis: Early satiety, nausea, bloating; less severe than in diabetic autonomic neuropathy
Sudomotor Failure
- Anhidrosis: Reduced or absent sweating, particularly in the lower extremities; demonstrated on thermoregulatory sweat test and QSART
- Heat intolerance: Impaired thermoregulation due to inability to sweat; risk of hyperthermia
Features That Should Prompt Reconsideration of PAF Diagnosis
- Parkinsonism: Bradykinesia, rigidity, or tremor → consider PD with autonomic failure
- Cerebellar ataxia: Gait ataxia, dysmetria, scanning speech → MSA-C
- Rapid progression: Severe disability within 1–3 years suggests MSA rather than PAF
- Stridor or respiratory failure: Vocal cord abductor paralysis is characteristic of MSA, not PAF
- Cognitive decline: Progressive dementia with visual hallucinations → DLB
- REM sleep behavior disorder: While not excluding PAF, RBD increases the probability of future conversion to PD or DLB
- Subacute onset: Weeks to months rather than years → autoimmune autonomic ganglionopathy (check ganglionic AChR antibodies)
Phenoconversion: The Central Prognostic Concern
The most important long-term consideration in PAF is the risk of phenoconversion — the development of additional neurologic features signaling evolution into a more widespread neurodegenerative disease. Prospective studies indicate that 14–34% of patients initially diagnosed with PAF will develop motor, cerebellar, or cognitive features over 5–10 years of follow-up.
| Phenoconversion Target | Estimated Risk | Clinical Clues | Biomarker Predictors |
|---|---|---|---|
| Parkinson Disease | ~10–15% over 5–10 years | Subtle bradykinesia, rest tremor, rigidity; anosmia; constipation preceding motor symptoms | Abnormal DAT scan; abnormal cardiac MIBG (reduced uptake); positive CSF alpha-synuclein SAA |
| Dementia with Lewy Bodies | ~5–15% over 5–10 years | Fluctuating cognition; visual hallucinations; REM sleep behavior disorder | Abnormal cardiac MIBG (reduced); positive CSF alpha-synuclein SAA; occipital hypometabolism on FDG-PET |
| Multiple System Atrophy | ~5–10% over 5–10 years | Cerebellar ataxia; parkinsonism with poor levodopa response; stridor; rapid progression | Preserved cardiac MIBG (normal uptake — preganglionic lesion); putaminal abnormalities on MRI |
Biomarkers for Predicting Phenoconversion
- REM sleep behavior disorder (RBD): Present in 30–50% of PAF patients; strong predictor of conversion to PD or DLB (not MSA); confirmed by polysomnography
- Cardiac MIBG scintigraphy:
- Reduced uptake (postganglionic denervation) → favors PD or DLB conversion
- Preserved uptake (intact postganglionic, preganglionic lesion) → favors MSA conversion
- DAT scan (DaTscan): Reduced striatal dopamine transporter binding suggests prodromal PD; may detect nigrostriatal degeneration before clinical parkinsonism
- CSF alpha-synuclein seed amplification assay (SAA): Emerging biomarker; detects misfolded alpha-synuclein in CSF; high sensitivity and specificity for synucleinopathies; may predict rate of progression
- Olfactory testing: Hyposmia/anosmia is a prodromal feature of PD and DLB; normal olfaction may favor MSA conversion or stable PAF
- FDG-PET: Occipital hypometabolism suggests DLB; putaminal and cerebellar changes suggest MSA
Diagnosis
PAF is a diagnosis of exclusion, requiring demonstration of generalized autonomic failure without evidence of a central neurodegenerative disorder. The diagnosis is provisional because phenoconversion can occur years after initial presentation.
Diagnostic Criteria (Consensus)
- Progressive autonomic failure documented by autonomic testing (orthostatic hypotension, cardiovagal dysfunction, sudomotor failure)
- No significant motor (parkinsonism), cerebellar (ataxia), or cognitive (dementia) deficits on neurologic examination
- No identifiable secondary cause of autonomic failure (diabetes, amyloid, autoimmune, medication-induced)
- Disease duration sufficient to exclude early MSA (which can present with isolated autonomic failure initially)
Key Diagnostic Investigations
| Investigation | Expected Finding in PAF | Differentiating Value |
|---|---|---|
| Supine plasma norepinephrine | Low (<100 pg/mL) — peripheral postganglionic denervation | Distinguishes from MSA (normal or mildly low supine NE, reflecting central/preganglionic lesion) |
| Standing plasma norepinephrine | Fails to rise appropriately (<2-fold increase from supine) | Confirms postganglionic sympathetic failure |
| Cardiac MIBG scintigraphy | Reduced uptake (postganglionic cardiac sympathetic denervation) | Reduced in PAF, PD, DLB; preserved in MSA |
| Autonomic reflex screen | Severe adrenergic failure (absent Valsalva overshoot); cardiovagal failure (reduced HR variability); sudomotor failure (reduced QSART) | Quantifies severity; pattern may help localize (postganglionic pattern) |
| Thermoregulatory sweat test | Diffuse or length-dependent anhidrosis | Combined with QSART: both abnormal = postganglionic pattern (PAF, PD); TST abnormal + QSART normal = preganglionic (MSA) |
| MRI brain | Normal (no putaminal, cerebellar, or pontine atrophy) | Putaminal and pontine atrophy suggest MSA; cortical atrophy may suggest DLB |
| Polysomnography | RBD present in 30–50% (risk factor for phenoconversion) | RBD presence increases monitoring frequency |
| DAT scan | Normal (or borderline reduced in prodromal PD) | Abnormal scan suggests evolving PD; may detect subclinical nigrostriatal loss |
| Ganglionic AChR antibodies | Negative | Positive in autoimmune autonomic ganglionopathy (important differential) |
Differential Diagnosis
| Condition | Key Distinguishing Features From PAF |
|---|---|
| MSA | Cerebellar ataxia or levodopa-poor-responsive parkinsonism; stridor; rapid progression; preserved cardiac MIBG; normal/mildly reduced supine NE; putaminal/pontine atrophy on MRI |
| PD with autonomic failure | Motor features of parkinsonism (bradykinesia, rigidity, tremor, asymmetric onset); levodopa-responsive; abnormal DAT scan |
| DLB | Fluctuating cognition, visual hallucinations, parkinsonism, RBD; cognitive deficits on formal testing |
| Autoimmune autonomic ganglionopathy | Subacute onset (weeks to months); ganglionic AChR antibodies positive; sicca symptoms; pupillary abnormalities; may respond to immunotherapy |
| Diabetic autonomic neuropathy | Known diabetes; concurrent sensorimotor neuropathy; autonomic failure correlates with neuropathy severity |
| Amyloid neuropathy | Length-dependent painful sensorimotor neuropathy; cardiomyopathy; TTR mutation or AL amyloid on biopsy |
Treatment
There is no disease-modifying therapy for PAF. Treatment is directed at managing the manifestations of autonomic failure, with orthostatic hypotension being the primary therapeutic target. Management follows the same principles as neurogenic OH treatment, with the additional challenge of balancing supine hypertension.
Orthostatic Hypotension Management
- Non-pharmacologic measures (foundation): Elevate head of bed 10–15 degrees, compression garments (abdominal binder preferred), fluid intake 2–3 L/day, sodium supplementation 6–10 g/day, rise slowly with counter-maneuvers, small frequent meals, avoid triggers (heat, alcohol, large meals)
- Midodrine: 2.5–10 mg TID (first-line pharmacotherapy); alpha-1 agonist for peripheral vasoconstriction
- Droxidopa: 100–600 mg TID (FDA-approved for nOH in synucleinopathies including PAF); replaces deficient norepinephrine
- Fludrocortisone: 0.05–0.2 mg daily; volume expansion; monitor potassium; significant supine HTN risk
- Pyridostigmine: 30–60 mg TID; modest effect; advantage of not worsening supine HTN
Supine Hypertension Management
- Elevate head of bed (single most effective intervention)
- Short-acting bedtime antihypertensives: nitroglycerin patch, losartan, or hydralazine
- Avoid taking vasopressor medications late in the day
- Accept mild-to-moderate supine HTN if orthostatic function is improved
Other Autonomic Symptom Management
- Urinary retention: Clean intermittent self-catheterization if post-void residual >100–150 mL; avoid anticholinergics for urgency (worsen retention)
- Constipation: High-fiber diet, adequate hydration, polyethylene glycol (MiraLAX), prucalopride; avoid stimulant laxatives chronically
- Erectile dysfunction: Phosphodiesterase-5 inhibitors (sildenafil, tadalafil) — caution: may worsen OH
- Anhidrosis: Avoid overheating; cooling vests; environmental temperature control
Monitoring and Follow-Up
Surveillance Protocol for Phenoconversion
- Neurologic examination: Every 6–12 months; specifically assess for subtle parkinsonism (finger tapping, gait), cerebellar signs, and cognition
- Sleep study (polysomnography): At baseline and if new symptoms suggest RBD (dream enactment, violent sleep behavior)
- Cognitive screening: Montreal Cognitive Assessment (MoCA) annually; formal neuropsychological testing if decline suspected
- Olfactory testing: UPSIT or Sniffin' Sticks; hyposmia may herald PD or DLB
- DAT scan: Consider if subtle parkinsonism emerges; abnormal result suggests evolving PD
- Cardiac MIBG: May be repeated if clinical features suggest evolution toward MSA (expected to remain abnormal in PAF but preserved in MSA)
- CSF alpha-synuclein SAA: Emerging role in predicting phenoconversion; may become standard monitoring tool
- Counsel patients: Explain the possibility of phenoconversion without causing undue anxiety; frame as proactive monitoring for early intervention
Prognosis
- Natural history: Slowly progressive autonomic failure over years to decades; generally more indolent than MSA
- Phenoconversion: 14–34% over 5–10 years; once conversion occurs, prognosis follows the natural history of the target disease (PD, DLB, or MSA)
- Mortality: Primarily related to complications of autonomic failure (falls, syncope-related injuries, cardiovascular events) and to phenoconversion
- Patients who remain "pure" PAF: Can maintain reasonable quality of life with optimal autonomic symptom management; survival comparable to age-matched population when OH is well-controlled
- Predictors of phenoconversion: Presence of RBD (strongest predictor), abnormal DAT scan, subtle motor findings, positive CSF SAA, preserved cardiac MIBG (toward MSA)
References
- Kaufmann H, Norcliffe-Kaufmann L, Palma JA, et al. Natural history of pure autonomic failure: a United States prospective cohort. Ann Neurol. 2017;81(2):287-297.
- Singer W, Berini SE, Sandroni P, et al. Pure autonomic failure: predictors of conversion to clinical CNS involvement. Neurology. 2017;88(12):1129-1136.
- Coon EA, Singer W, Low PA. Pure autonomic failure. Mayo Clin Proc. 2019;94(10):2087-2098.
- Gibbons CH, Freeman R. Clinical implications of delayed orthostatic hypotension: a 10-year follow-up study. Neurology. 2015;85(16):1362-1367.
- Goldstein DS, Holmes C, Sharabi Y, Wu T. Survival in synucleinopathies: a prospective cohort study. Neurology. 2015;85(18):1554-1561.
- Palma JA, Norcliffe-Kaufmann L, Kaufmann H. Diagnosis of multiple system atrophy. Auton Neurosci. 2018;211:15-25.
- Donadio V, Incensi A, Cortelli P, et al. Skin sympathetic fiber alpha-synuclein deposits: a potential biomarker for pure autonomic failure. Neurology. 2013;80(8):725-732.
- Figueroa JJ, Singer W, Parsaik A, et al. Multiple system atrophy: prognostic indicators of survival. Mov Disord. 2014;29(9):1151-1157.
- Norcliffe-Kaufmann L, Kaufmann H. Is pure autonomic failure pure? Neurology. 2017;88(12):1102-1103.
- Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407-417.
- Benarroch EE. The clinical approach to autonomic failure in neurological disorders. Nat Rev Neurol. 2014;10(7):396-407.
- Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009;119(1):139-146.